2012 pay: $13.2 million
2011 pay: $11.2 million
Credit Roche ($RHHBY) CEO Severin Schwan's dogged commitment to diagnostics for the company's consistent dominance in the industry. Last year, Roche raked in $11.2 billion from its diagnostics arm, sopping up a 20% world market share thanks in large part to Schwan's emphasis on pairing the company's pipeline treatments with companion assays.
However, Roche's diabetes unit, which includes the company's insulin pumps and glucose monitors, has continued to struggle, sliding 3% to $2.8 billion in 2012. Roche blames the trouble on European reimbursement cuts for monitors and intensified pricing pressures around the globe. But the company is taking proactive steps, cutting 100 jobs and reforming its diabetes operations to move blood glucose test development to its Indianapolis diagnostics headquarters and shift insulin pump R&D to Germany.
In 2012, Schwan made a $4.3 million base salary, a $2.7 million bonus, another $4.3 million in stock appreciation rights and about $1.2 million in nonequity securities.
- check out Roche's annual report (PDF)
Roche Diagnostics leaps 4% in 2012, snags 20% market share
Roche Diagnostics cutting 100 jobs in diabetes restructuring
Roche invests $258M-plus into Germany Dx plant expansion